Effect of 1-aminobenzotriazole on the in vitro metabolism and single-dose pharmacokinetics of chlorzoxazone, a selective CYP2E1 substrate in Wistar rats

Xenobiotica

Volumn 35, Issue 8, 2005, Pages 825-838

  Muzeeb, S ^a   Pasha, M K ^a   Basha, S J S ^a   Mullangi, R ^a   Srinivas, N R ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

1 aminobenzotriazole; Chlorzoxazone; Enzyme kinetics; Hydroxychlorzoxazone; In vitro metabolism; Pharmacokinetics; Rats

Indexed keywords

1 AMINOBENZOTRIAZOLE; 6 HYDROXYCHLORZOXAZONE; CHLORZOXAZONE; CYTOCHROME P450 2E1; DRUG METABOLITE;

ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; ENZYME BINDING; ENZYME KINETICS; ENZYME SPECIFICITY; ENZYME SUBSTRATE; IN VITRO STUDY; LIVER MICROSOME; MALE; MUSCLE RELAXATION; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; SINGLE DRUG DOSE;

ANIMALS; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; HUMANS; KINETICS; MALE; MICROSOMES, LIVER; RATS; RATS, WISTAR; TRIAZOLES;

ANIMALIA; RATTUS NORVEGICUS;

EID: 27944459279     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250500307301     Document Type: Article

References (50)

1. Balani SK, Li P, Nguyen J, Cardoza K, Zeng H, Mu DX, Wu JT, Gan LS, Lee FW. 2004. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. Drug Metabolism and Disposition 32:1092-1095.
2. Balani SK, Zhu T, Yang TJ, Liu Z, He B, Lee FW. 2002. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs and monkeys. Drug Metabolism and Disposition 30:1059-1062.
3. Bolt HM, Ross PH, Thier R. 2003. The cytochrome P-450 isozyme CYP2E1 in the biological processing of industrial chemicals: Consequences for occupational and environmental medicine. International Archives of Occupational and Environmental Health 76:174-185.
4. Carriere V, Goasduff T, Ratanasavahh D, Morel F, Gautier JC, Guillouzo A, Beaune P, Berthou F. 1993. Both cytochrome P4502E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chemical Research in Toxicology 6:852-857.
5. Carriere V, Berthou F, Baird S, Belloc C, Beaune P, De Waziers I. 1996. Human cytochrome P450 2E1 (CYP2E1): From genotype to phenotype. Pharmacogenetics 6:203-211.
6. Castillo T, Koop DR, Kamimura S, Triadafilopoulos G, Tsukamoto H. 1992. Role of cytochrome P-450 2E1 in ethanol-, carbon tetrachloride-, and iron-dependent microsomal lipid peroxidation. Hepatology 16:992-996.
7. Chen L, Yang CS. 1996. Effects of cytochrome P450 2E1 modulators on the pharmacokinetics of chlorzoxazone and 6-hydroxychlorzoxazone in rats. Life Sciences 58:1575-1585.
8. Conney AH, Burns JJ. 1960. Physiological disposition and metabolic fate of chlorzoxazone (Paraflex) in man. Journal of Pharmacology and Experimental Therapeutics 128:340-343.
9. Constan AA, Sprankle CS, Peters JM, Kedderis GL, Everitt JI, Wong BA, Gonzalez FL, Butterworth BE. 1999. Metabolism of chloroform by CYP 2E1 is required for induction of toxicity in the liver, kidney and nose of male mice. Toxicology and Applied Pharmacology 160:120-126.
10. Dai Y, Rashba-Step J, Cederbaum AI. 1993. Stable expression of human cytochrome P4502E1 in HepG2 cells: Characterization of catalytic activities and production of reactive oxygen intermediates. Biochemistry 32:6928-6937.
11. Desiraju RK, Renzi NL Jr, Nayak RK, Ng KT. 1983. Pharmacokinetics of chlorzoxazone in humans. Journal of Pharmaceutical Sciences 72:991-994.
12. Di Re J, Lee C, Riddick DS. 1999. Lack of mechanism-base inactivation of rat hepatic microsomal cytochrome P450 by doxorubicin. Canadian Journal of Physiology and Pharmacology 77:589-597.
13. Ekstrom G, Ingelman-Sundberg M. 1989. Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome p-450 (P-450IIE1). Biochemistry and Pharmacology 38:1313-1319.
14. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. 1996. Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine and noranti-pyrine formation. Clinical Pharmacology and Therapeutics 59:613-623.
15. Garton KJ, Yuen P, Meinwald J, Thummel KE, Kharasch ED. 1995. Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1. Drug Metabolism and Disposition 23:1426-1430.
16. Gibaldi M, Perrier D. 1982. Pharmacokinetics. 2nd ed. New York: Dekker.
17. Gorski JC, Jones DR, Wrighton AS, Hall SD. 1997. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 27:243-256.
18. Guengerich FP, Kim DH, Iwasaki M. 1991. Role of human cytochrome P450 2E1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology 4:168-179.
19. Huijzer JC, Adams JD, Jaw JY, Yost GS. 1989. Inhibition of 3-methylindole bioactivation by the cytochrome P450 suicide substrates 1-aminobenzotriazole and alpha-methylbenzylaminobenzotriazole. Drug Metabolism and Disposition 17:37-42.
20. Jackson TE, Lilly PD, Recio L, Schlosser PM, Medinsky MA. 2000. Inhibition of cytochrome P450 2E1 decreases, but does not eliminate, genotoxicity mediated by 1,3-butadiene. Toxicological Sciences 55:266-273.
21. Jayyosi Z, Knoble D, Muc M, Erick J, Thomas PE, Kelley M. 1995. Cytochrome P-450 2E1 is not the sole catalyst of chlorzoxazone hydroxylation in rat liver microsomes. The Journal of Pharmacology and Experimental Therapeutics 273:1156-1161.
22. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. 1993. Single dose of disulfiram inhibition of chlorzoxazone metabolism: A clinical probe for P450 2E1. Clinical Pharmacology and Therapeutics 53:643-650.
23. Kharasch ED, Thummel KE, Mautz D, Bosse S. 1994. Clinical enflurane metabolism by cytochrome P450 2E1. Clinical Pharmacology and Therapeutics 55:434-440.
24. Knickle LC, Bend JR. 1992. Dose-dependent, mechanism-based inactivation of cytochrome P450 monooxygenases in vivo by 1-aminobenzotriazole in liver, lung and kidneys of untreated, Phenobarbital-treated and α-napthoflavone- treated guinea pigs. Canadian Journal of Physiology and Pharmacology 70:1610-1617.
25. Koop DR. 1992. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB 6:724-730.
26. Lee SST, Buters JTM, Pineau T, Fernandez-Salguero P, Gonzalez FJ. 1996, Role of CYP2E1 in the hepatotoxicity of acetaminophen. Journal of Biological Chemistry 271:12063-12067.
27. Loi CM, Day JD, Jue SG, Bush ED, Costello P, Dewey IV, Vestal RE. 1989. Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. Clinical Pharmacology and Therapeutics 45:476-486.
28. Lucas D, Ferrara R, Gonzalez E, Bodenez P, Albores A, Manno M, Berthou R. 1999. Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics 9:377-388.
29. Marczylo T, Ioannides C. 1999. Evidence for the presence of a microsomal NADH-dependent enzyme system that can bioactivate aromatic amines in the liver of rats and mice. Toxicology 134:127-141.
30. Mathews JN, Raymer JH, Velez GR, Garner CE, Bucher JR. 1996. The influence of cytochrome P450 enzyme activity on the composition and quantity of volatile oranics in expired breath. Biomarkers 1:196-201.
31. Matzke GR, Frye FR, Early JJ, Straka RJ, Carson SW. 2000. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 20:182-190.
32. Meschter CL, Mico BA, Mortillo M, Feldman D, Garland WA, Riley JA, Kaufman LS. 1994. A 13-week toxicologic and pathologic evaluation of prolonged cytochrome P450 inhibition by 1-aminobenzotriazole in male rats. Fundamental Applications of Toxicology 22:369-381.
33. Mico BA, Federowicz DA, Ripple MG, Kerus W. 1988. In vivo inhibition of oxidative drug metabolism by and acute toxicity of 1-aminobenzotriazole (ABT). A tool for biochemical toxicology. Biochemistry and Pharmacology 37:2515-2519.
34. Mugford CA, Mortillo M, Mico BA, Tarloff JB. 1992. 1-Aminobenzotriazole destruction of hepatic and renal cytochrome P450 in male SD rats. Fundamental Applications of Toxicology 19:43-49.
35. Mugford CA, Tarloff JB. 1995. Contribution of oxidative and deacetylation to the bioactivation of acetaminophen in vitro in liver and kidneys from male and female SD rats. Drug Metabolism and Disposition 23:290-294.
36. Nolin TD, Gastonguay MR, Bies RR, Matzke GR, Frye RF. 2003. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies. Clinical Pharmacology and Therapeutics 74:555-568.
37. Nomeir AA, Ruegg C, Shoemaker M, Favreau LV, Palamande JR, Silber P, Lin CC. 2001. Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metabolism and Disposition 29:748-753.
38. Ono S, Hatamak T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ. 1995. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 5:143-150.
39. Ortiz de Montellano PR, Mathews, JM. 1981. Autocatalytic alkylation of the cytochrome P450 prosthetic haem group by 1-aminobenzotriazole. Biochemical Journal 195:761-764.
40. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. 1990. Hydroxylation of chlorzoxazone, as a specific probe for human liver cytochrome P-450 2E1. Chemical Research in Toxicology 3:566-573.
41. Poloyac SM, Tosheva RT, Gardner BM, Shedlofsky SI, Blouin AR. 1999. The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans. Clinical Pharmacology and Therapeutics 66:554-562.
42. Rao MNVS, Biju B, Khan AA, Mujeeb S, Mullangi R, Srinivas, NR. 2003. Open access generic method for continuous determination of major human CYP 450 substrates/metabolites and its application in drug metabolism studies. Xenobiotica 33:1233-1245.
43. Raucy JE, Lasker JM, Lieber CS, Black M. 1989. Acetaminophen activation by human liver cytochrome P450 2E1 and 1A2. Archives in Biochemistry and Biophysics 271:270-283.
44. Raucy JL, Kraner JC, Lasker JM. 1993. Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Critical Reviews in Toxicology 23:1-20.
45. Rockich K, Blouin R. 1999. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats. Drug Metabolism and Disposition 27:1074-1077.
46. Spracklin DK, Hankins DC, Fisher JM, Thummel KE, Kharasch ED. 1997. Cytochrome P4502E1 is the principal catalyst of human oxidative halothane metabolism in vitro. Journal of Pharmacology and Experimental Therapeutics 281:400-411.
47. Su P, Kaushal KM, Kroetz DL. 1998. Inhibition of renal arachidonic acid omega-hydroxylase activity with ABT reduces blood pressure in the SHR. American Journal of Physiology 275:R426-438.
48. Town C, Henderson L, Chang D, Mortillo M, Garland W. 1993. Distribution of 1-aminobenzotriazole in male rats after administration of an oral dose. Xenobiotica 23:383-390.
49. Wong SG, Lin EH, Marks GS. 1999. Cytochrome sources of N-alkylprotoporphyrin IX after administration of porphyrnogenic xenobiotics to rats. Drug Metabolism and Disposition 27:960-965.
50. Xu D, Voigt JM, Mico BA, Kominami S, Takemori S, Colby HD. 1994. Biochemistry Pharmacology 48:1421-1426.